Ephedra-containing dietary supplement across-the-board label warning suggested by FDA.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRA SUPPLEMENT ACROSS-THE-BOARD LABEL WARNING STATEMENT would be required for all dietary supplements containing ephedrine alkaloids under a June 4 FDA proposed rule. The warning statement advises consumers to consult a "health care provider" before using ephedrine alkaloid-containing products if they are pregnant or nursing or have: heart disease; thyroid disease; diabetes; high blood pressure; depression or other psychiatric condition; glaucoma; difficulty in urinating; prostate enlargement; or a seizure disorder.
You may also be interested in...
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C